Industry

Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results

INDIANAPOLIS, April 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and... Continue Reading

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type TTR

PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in patients with variant and... Continue Reading

Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study

THE WOODLANDS, Texas, March 03, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced topline results from the PROGRESS Phase 2b study evaluating pilavapadin (LX9211), an oral, non-opioid investigational adaptor-associated kinase 1 (AAK1) inhibitor in adult... Continue Reading

Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients

INDIANAPOLIS, Feb. 25, 2025 /PRNewswire/ -- Today Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program.1 Lilly also reduced the price of the 2.5 mg and 5 mg vials.... Continue Reading

https://liposorber.com/posts/expanded-indication-for-kanekas-liposorber-la-15-system/

New York, January 29, 2025We are pleased to announce an important update regarding Kaneka’s LIPOSORBER® LA-15 System Indications for clinically diagnosed Familial Hypercholesterolemic patients. As part of our ongoing commitment to advance patient care and support healthcare providers in... Continue Reading

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight

Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg... Continue Reading

TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with FCS

CARLSBAD, Calif., December 19, 2024 -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA™ (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare,... Continue Reading

AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE

THOUSAND OAKS, Calif., Nov. 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide (maridebart cafraglutide, formerly AMG 133), an investigational antibody peptide conjugate subcutaneously administered... Continue Reading

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA

PALO ALTO, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a new type of biopharmaceutical company focused on genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) approved Attruby™ (acoramidis), an... Continue Reading

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes

PALO ALTO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, presented positive initial outcomes from the ATTRibute-CM open-label extension... Continue Reading

BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramid

PALO ALTO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, presented a post-hoc analysis evaluating the effect of acoramidis on the... Continue Reading

Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant...

Basel, August 28, 2024 – Novartis announced today positive topline results from twice-yearly* Leqvio® (inclisiran) in the Phase III V-MONO study, which met its primary endpoints. Leqvio monotherapy achieved clinically meaningful and statistically significant low-density lipoprotein... Continue Reading